Live from the NIH registry
Studies recruiting near Grand Rapids right now
Top 25 of 461 recruiting studies, sorted by proximity — each links to its official registry page
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Cancer Research Consortium of West Michigan — Grand Rapids, Michigan (0.6 mi)
· Sponsor: American Society of Clinical Oncology
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NK-Cell Lymphoma, NK-Cell Leukemia
EARLY/Phase 1
Interventional 40 participants sought
Helen De Vos — Grand Rapids, Michigan (0.6 mi)
· Sponsor: New York Medical College
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Multilevel Community-Centered Intervention to Reduce Pregnancy Related and Associated Morbidity and Mortality (PRAMM) Disparities
Provider Confidence, Provider Behavior
N/A
Interventional 480 participants sought
Strong Beginings — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Michigan State University
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Phase 1
Interventional 364 participants sought
START Midwest — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Astellas Pharma Inc
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Phase 2
Interventional 100 participants sought
START Midwest — Grand Rapids, Michigan (0.6 mi)
· Sponsor: C4 Therapeutics, Inc.
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Focal Segmental Glomerulosclerosis
N/A
Interventional 35 participants sought
Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Kaneka Medical America LLC
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
Systemic Lupus Erythematosus of Childhood (Disorder)
N/A
Interventional 175 participants sought
Helen Devos Children's Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Michigan State University
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: NRG Oncology
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Phase 2
Interventional 1,431 participants sought
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center — Wyoming, Michigan (4.2 mi)
· Sponsor: Eli Lilly and Company
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1
Interventional 694 participants sought
START Midwest /ID# 248685 — Grand Rapids, Michigan (0.6 mi)
· Sponsor: AbbVie
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy, Fuchs
Phase 2
Interventional 28 participants sought
DTX-168-201 Study Site — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Design Therapeutics, Inc.
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Cancer, Bladder Cancer
Phase 2, Phase 3
Interventional 630 participants sought
Research Site — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Daiichi Sankyo
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
N/A
Interventional 739 participants sought
Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Advanced or Metastatic Colorectal Cancer
Phase 1, Phase 2
Interventional 225 participants sought
Start Midwest — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Janssen Research & Development, LLC
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2
Interventional 396 participants sought
Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-Small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Research Site — Grand Rapids, Michigan (0.6 mi)
· Sponsor: AstraZeneca
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Interventional 120 participants sought
START Midwest/The Cancer and Hematology Center — Grand Rapids, Michigan (0.6 mi)
· Sponsor: SystImmune Inc.
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Atopic Dermatitis
N/A
Observational 1,000 participants sought
Galderma Investigational Site 7108 — Grandville, Michigan (6.5 mi)
· Sponsor: Galderma R&D
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Colorectal Cancer, Colorectal Cancer (CRC)
Phase 1
Interventional 80 participants sought
START Midwest — Grand Rapids, Michigan (0.6 mi)
· Sponsor: Cartography Biosciences
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
Phase 3
Interventional 170 participants sought
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)